Status:
WITHDRAWN
Aromatase Inhibitors for Treatment of Uterine Leiomyomas
Lead Sponsor:
American University of Beirut Medical Center
Conditions:
Symptomatic or Large Uterine Fibroids
Eligibility:
FEMALE
50-55 years
Phase:
PHASE1
Brief Summary
Fibroids are benign tumors that might results in bleeding. Surgery is their definitive treatment. Some medical therapies have been tried for women who wish to preserve their uterus. Recent reports hav...
Detailed Description
Fibroids (leiomyomas) are benign tumors that originate in the musculature of the uterus. They are the most common cause for removal of the uterus in women. Surgery is the final definitive treatment of...
Eligibility Criteria
Inclusion
- 1\. Perimenopausal women (≥ 50 years) with symptomatic uterine leiomyomas (menometrorrhagia, pressure symptoms, urinary retention, pelvic pain) or those with large leiomyomas ≥ 7 cms
Exclusion
- Women \<50 years of age
- Postmenopausal women
- Women with impaired renal function
- Oral treatment with any type of estrogen or progesterone more recently than 1 month
- History of venous thromboembolism
- Any contraindication for Magnetic Resonance Imaging (MRI)
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00945360
Start Date
March 1 2011
End Date
May 1 2011
Last Update
July 13 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
American University of Beirut
Beirut, Lebanon